Table 1 Responses from retina specialists having experience with CSCR management:
From: Real-world practice patterns of eplerenone use for central serous chorioretinopathy
Variable | Value | |
|---|---|---|
Total Number of responses | 241 | |
Years of clinical experience (Mean ± SD) | 15.69 ± 9.589 | |
Geographic location (n, %) | India | 122 (51) |
Rest | 119 (49) | |
North America | 28 (12) | |
South America | 8 (3) | |
Asia (other than India) | 35 (14) | |
Europe | 44 (18) | |
Africa | 1 (1) | |
Pacific | 3 (1) | |
No. of new patients with CSCR seen in a month (n, %) | 0–10 | 157 (65) |
11–20 | 62 (26) | |
> 20 | 22 (9) | |
Acute cases of CSCR seen in a month (n, %) | 0–10 | 229 (95) |
11–20 | 9 (4) | |
> 20 | 3 (1) | |
Chronic cases of CSCR seen in a month (n, %) | 0–10 | 202 (84) |
11–20 | 33 (14) | |
> 20 | 6 (2) | |
Treatment modalities used in CSCR (n, %) | Observation | 215 (89) |
PDT | 92 (38) | |
Focal laser | 140 (58) | |
Subthreshold MP laser | 80 (33) | |
AntiVEGF | 61 (25) | |
Eplerenone | 149 (62) | |
Others | 32 (13) | |
Availability of PDT in practice (n, %) | No, not available | 136 (56) |
Yes, but difficult to get the drug | 75 (31) | |
Yes, easily available | 30 (13) |